XML 99 R65.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Equity Investments (Details) |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Aug. 15, 2024 USD ($) | Feb. 07, 2023 $ / shares shares | Apr. 30, 2024 USD ($) shares | Apr. 30, 2022 USD ($) shares | Jul. 31, 2021 USD ($) shares | May 31, 2021 USD ($) shares | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($)
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Mark-to-market gain (loss) |  |  |  |  |  |  | $ 5,683,000 | $ 53,461,000 | $ (18,084,000)
Cash payments to purchase of shares |  |  |  |  |  |  | 3,072,000 | 4,125,000 | 600,000
Nimbus Therapeutics, LLC |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Non-marketable equity security |  |  |  |  |  |  | 2,436,000 | 1,928,000 |
Unrealized (loss) gain |  |  |  |  |  |  | 508,000 | 1,928,000 | 0
Realized gain |  |  |  |  |  |  |  | 147,213,000 |
Morphic Holding, Inc. |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Proceeds from sale of equity securities | $ 47,588,000 |  |  |  |  |  |  |  |
Mark-to-market gain (loss) |  |  |  |  |  |  | 23,474,000 | 1,778,000 | (17,226,000)
Marketable securities |  |  |  |  |  |  | 0 | 24,114,000 |
Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Non-marketable equity security |  |  |  |  |  |  | 4,498,000 | 1,700,000 |
Mark-to-market gain (loss) |  |  |  |  |  |  | (202,000) | 0 | 0
Structure Therapeutics |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Mark-to-market gain (loss) |  |  |  |  |  |  | (18,096,000) | 49,755,000 | $ (858,000)
Marketable securities |  |  |  |  |  |  | $ 36,202,000 | $ 55,509,000 |
Series B preferred stock | Structure Therapeutics |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Number of preferred shares purchased | shares |  |  |  | 148,210 | 494,035 |  |  |  |
Cash payments to purchase of shares |  |  |  | $ 600,000 | $ 2,000,000 |  |  |  |
Conversion ratio |  | 1 |  |  |  |  |  |  |
Series B preferred stock | Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Number of preferred shares purchased | shares |  |  |  |  |  | 631,377 |  |  |
Cash payments to purchase of shares |  |  |  |  |  | $ 1,700,000 |  |  |
ADR | Structure Therapeutics |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Number of shares purchased | shares |  | 275,000 |  |  |  |  |  |  |
Purchase price (in USD per share) | $ / shares |  | $ 15.00 |  |  |  |  |  |  |
Stock split, conversion ratio |  | 3 |  |  |  |  |  |  |
Series C preferred stock | Ajax Therapeutics, Inc |  |  |  |  |  |  |  |  |
Debt and Equity Securities, FV-NI [Line Items] |  |  |  |  |  |  |  |  |
Number of preferred shares purchased | shares |  |  | 1,416,450 |  |  |  |  |  |
Cash payments to purchase of shares |  |  | $ 3,000,000 |  |  |  |  |  |

X
- Definition American Depository Shares Purchased, Price Per Share + References No definition available. + Details
Name: | sdgr_AmericanDepositorySharesPurchasedPricePerShare
Namespace Prefix: | sdgr_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of preferred shares purchased. + References No definition available. + Details
Name: | sdgr_NumberOfPreferredSharesPurchased
Namespace Prefix: | sdgr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Shares Purchased + References No definition available. + Details
Name: | sdgr_NumberOfSharesPurchased
Namespace Prefix: | sdgr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiRealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion for each share of preferred stock to be converted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details
Name: | us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_NimbusTherapeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_MorphicHoldingIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_AjaxTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=sdgr_StructureTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sdgr_StructureTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=dei_AdrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |